Whitfield Roy A

Whitfield Roy A is listed in filings as Director at Nektar Therapeutics. This profile follows SEC Form 4 activity through Oct 1, 2025, including 2 public disclosures. Recent filings connect the profile to Nektar Therapeutics (NKTR). The current snapshot covers public activity from Jan 17, 2025 to Oct 1, 2025. Reported amounts are shown as $151.2K to $455.2K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.